Lipid encapsulated interfering RNA
First Claim
Patent Images
1. An nucleic acid-lipid particle, said nucleic acid-lipid particle comprising:
- (a) an interfering RNA;
(b) a cationic lipid of Formula I and having the following structure;
wherein;
R1 and R2 are independently selected from the group consisting of;
H and C1-C3 alkyls; and
R3 and R4 are independently selected from the group consisting of alkyl groups having from about 10 to about 20 carbon atoms, wherein at least one of R3 and R4 comprises at least two sites of unsaturation;
(c) a non-cationic lipid; and
(d) a conjugated lipid that inhibits aggregation of particles.
4 Assignments
0 Petitions
Accused Products
Abstract
The present invention provides lipid-based formulations for delivering, e.g., introducing, nucleic acid-lipid particles comprising an interference RNA molecule to a cell, and assays for optimizing the delivery efficiency of such lipid-based formulations.
-
Citations
37 Claims
-
1. An nucleic acid-lipid particle, said nucleic acid-lipid particle comprising:
-
(a) an interfering RNA;
(b) a cationic lipid of Formula I and having the following structure;
wherein;
R1 and R2 are independently selected from the group consisting of;
H and C1-C3 alkyls; and
R3 and R4 are independently selected from the group consisting of alkyl groups having from about 10 to about 20 carbon atoms, wherein at least one of R3 and R4 comprises at least two sites of unsaturation;
(c) a non-cationic lipid; and
(d) a conjugated lipid that inhibits aggregation of particles. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17)
-
-
18. A method of introducing an interfering RNA into a cell, said method comprising contacting said cell with a nucleic acid-lipid particle comprising
(a) said interfering RNA; -
(b) a cationic lipid of Formula I and having the following structure;
wherein;
R1 and R2 are independently selected from the group consisting of;
H and C1-C3 alkyls; and
R3 and R4 are independently selected from the group consisting of alkyl groups having from about 10 to about 20 carbon atoms, wherein at least one of R3 and R4 comprises at least two sites of unsaturation;
(c) a non-cationic lipid; and
(d) a conjugated lipid that inhibits aggregation of particles. - View Dependent Claims (19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32)
-
-
33. A method for in vivo delivery of interfering RNA, said method comprising administering to a mammalian subject a nucleic acid-lipid particle comprising:
-
(a) said interfering RNA;
(b) a cationic lipid of Formula I and having the following structure;
wherein;
R1 and R2 are independently selected from the group consisting of;
H and C1-C3 alkyls; and
R3 and R4 are independently selected from the group consisting of alkyl groups having from about 10 to about 20 carbon atoms, wherein at least one of R3 and R4 comprises at least two sites of unsaturation;
(c) a non-cationic lipid; and
(d) a conjugated lipid that inhibits aggregation of particles. - View Dependent Claims (34, 35, 36, 37)
-
Specification